The outlook for Syngene looks weak on a tough marco situation, global headwinds and falling VC funding, said UBS.
UBS downgrades Syngene to ‘sell’ on weak outlook, shares slip 3% on January 16, 2024 at 6:31 am
The outlook for Syngene looks weak on a tough marco situation, global headwinds and falling VC funding, said UBS.